indacaterol and Bronchial-Hyperreactivity

indacaterol has been researched along with Bronchial-Hyperreactivity* in 1 studies

Other Studies

1 other study(ies) available for indacaterol and Bronchial-Hyperreactivity

Article	Year
Bronchoprotective tolerance with indacaterol is not modified by concomitant tiotropium in persistent asthma. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2017, Volume: 47, Issue:10 Tiotropium is a long acting muscarinic antagonist (LAMA), licensed as triple therapy with inhaled corticosteroid and long-acting beta-agonist (ICS/LABA). There may be a synergistic benefit between LAMA and LABA as a consequence of receptor cross-talk, which in turn could modify beta-2 receptor downregulation and associated tolerance induced by LABA.. We hypothesize this mechanism may result in a reduction of airway hyperresponsiveness (AHR) when using triple therapy.. We evaluated 14 non-smoking asthmatics using an open-label, randomized crossover design. ICS with Indacaterol and Tiotropium (IND/TIO) vs ICS with Indacaterol (IND) over 4 weeks with challenge performed after first and last doses at trough.. Our data suggest that concomitant tiotropium does not modify the bronchoprotective tolerance induced by Indacaterol, in turn suggesting that cross-talk may not be clinically relevant when using triple therapy. This study was registered on clinicaltrials.gov as NCT02039011. Topics: Adult; Aged; Asthma; Biomarkers; Bronchial Hyperreactivity; Drug Therapy, Combination; Female; Humans; Indans; Male; Middle Aged; Muscarinic Antagonists; Quinolones; Respiratory Function Tests; Tiotropium Bromide; Treatment Outcome	2017

Article

Year

Bronchoprotective tolerance with indacaterol is not modified by concomitant tiotropium in persistent asthma.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2017, Volume: 47, Issue:10

Tiotropium is a long acting muscarinic antagonist (LAMA), licensed as triple therapy with inhaled corticosteroid and long-acting beta-agonist (ICS/LABA). There may be a synergistic benefit between LAMA and LABA as a consequence of receptor cross-talk, which in turn could modify beta-2 receptor downregulation and associated tolerance induced by LABA.. We hypothesize this mechanism may result in a reduction of airway hyperresponsiveness (AHR) when using triple therapy.. We evaluated 14 non-smoking asthmatics using an open-label, randomized crossover design. ICS with Indacaterol and Tiotropium (IND/TIO) vs ICS with Indacaterol (IND) over 4 weeks with challenge performed after first and last doses at trough.. Our data suggest that concomitant tiotropium does not modify the bronchoprotective tolerance induced by Indacaterol, in turn suggesting that cross-talk may not be clinically relevant when using triple therapy. This study was registered on clinicaltrials.gov as NCT02039011.

Topics: Adult; Aged; Asthma; Biomarkers; Bronchial Hyperreactivity; Drug Therapy, Combination; Female; Humans; Indans; Male; Middle Aged; Muscarinic Antagonists; Quinolones; Respiratory Function Tests; Tiotropium Bromide; Treatment Outcome

2017